Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | KDM6B | O15054 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832960 | 0.88 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL28613135 | 0.88 | ALDH1A1 (0.60) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL3961945 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL25827431 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL21786269 | 0.86 | ALDH1A1 (0.63) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL23639428 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL30465486 | 0.86 | KDM4E (0.57) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL4074620 | 0.86 | KDM4E (0.57) | ALDH1A1KDM4EGAAGLALMNA | |
| SCHEMBL12447815 | 0.84 | TSHR (0.52) | ALDH1A1KDM4EGAAGLAHSD17B10 | |
| SCHEMBL19838578 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KDM4EGAAGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-04-24 | — | — | US | disclosed |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-109071497-B | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3830079-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | The Trustees of Princeton University (US) | 2021-06-09 | — | — | EP | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2008004100-A2 | THERAPEUTIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | ALDH1A1 577/4885KDM4E 3841/4885GAA 1107/4885 |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | ALDH1A1 956/4885KDM4E 117/4885GAA 904/4885 |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | ALDH1A1 956/4885KDM4E 117/4885GAA 904/4885 |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | ALDH1A1 2675/4885KDM4E 1294/4885GAA 1568/4885 |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | ALDH1A1 956/4885KDM4E 117/4885GAA 904/4885 |
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | ALDH3A1, ALDH1A1, ALDH2 | ALDH1A1 2/4885KDM4E 2448/4885GAA 1693/4885 |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | ALDH3A1, ALDH2, ALDH1A1 | ALDH1A1 3/4885KDM4E 2577/4885GAA 1875/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | ALDH1A1 956/4885KDM4E 117/4885GAA 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.